Home > Cardiology > ACC 2019 > Interventional Cardiology > TAVR superior and non-inferior to SAVR in low-risk patients

TAVR superior and non-inferior to SAVR in low-risk patients

ACC 2019
PARTNER 3, Evolut Low Risk

Two landmark trials comparing transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in low-risk patients have shown promising results. The PARTNER 3 trial demonstrated that TAVR was superior to SAVR with regard to the reduction of death, stroke, or rehospitalisation at 1 year [1]. Results from the Evolut Low Risk trial showed that TAVR with the self-expanding CoreValve was non-inferior to SAVR [2].

The randomised, parallel PARTNER 3 trial aimed to evaluate TAVR compared with SAVR in low-risk patients with symptomatic severe aortic stenosis. A total of 1,000 patients were enrolled in the study with a median follow-up of 1 year. Mean patient age was 73 years, 30% of patients was female, and 31% had diabetes mellitus. The mean Society of Thoracic Surgeons (STS) risk score was 1.9% (score <4% denoted ‘low-risk’, with higher scores indicating a greater risk of death within 30 days after surgery). The inclusion and exclus...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on